Aptus Capital Advisors LLC Has $11.75 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Aptus Capital Advisors LLC increased its position in Johnson & Johnson (NYSE:JNJGet Rating) by 18.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 66,269 shares of the company’s stock after purchasing an additional 10,440 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Johnson & Johnson were worth $11,745,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Patron Partners LLC lifted its position in Johnson & Johnson by 12.7% in the first quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock worth $1,174,000 after purchasing an additional 747 shares during the period. Tandem Investment Advisors Inc. lifted its position in Johnson & Johnson by 4.8% in the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock worth $57,867,000 after purchasing an additional 15,003 shares during the period. Argent Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 6.6% during the first quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock valued at $3,504,000 after acquiring an additional 1,218 shares during the period. Exeter Financial LLC lifted its holdings in shares of Johnson & Johnson by 3.2% during the first quarter. Exeter Financial LLC now owns 26,431 shares of the company’s stock valued at $4,684,000 after acquiring an additional 819 shares during the period. Finally, Fusion Capital LLC lifted its holdings in shares of Johnson & Johnson by 7.8% during the first quarter. Fusion Capital LLC now owns 27,844 shares of the company’s stock valued at $4,935,000 after acquiring an additional 2,019 shares during the period. 68.78% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Down 0.4 %

Shares of NYSE:JNJ opened at $171.11 on Friday. The company has a 50 day moving average of $175.21 and a 200-day moving average of $174.55. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The stock has a market cap of $449.88 billion, a price-to-earnings ratio of 24.91, a P/E/G ratio of 3.32 and a beta of 0.59. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.14.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The business had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same period in the prior year, the business posted $2.48 earnings per share. Johnson & Johnson’s revenue was up 3.0% compared to the same quarter last year. On average, sell-side analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.64%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JNJ. Credit Suisse Group lifted their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Raymond James lifted their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Daiwa Capital Markets started coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating for the company. Finally, SVB Leerink cut their price target on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.